26th Aug 2025 11:57
(Alliance News) - EKF Diagnostics Holdings PLC on Tuesday reported the signing of three haematology contracts worth around EUR4.7 million, boosting its confidence in hitting its full-year targets.
Shares in the Cardiff-headquartered medical diagnostics company were up 6.0% at 28.66 pence on Tuesday morning in London.
EKF Diagnostics said the contracts will be delivered over the next one to two years, and are for the supply of haemoglobin analysers and related consumables.
All contracts have been secured by its distribution partners in Africa and Latin America. EKF said one of the contracts represents "a return to significant sales in Peru." It noted a sharp decline in the region owing to "geo-political factors within the country."
One contract represents the company's first sales in Uganda, with it also noting strong sales gross across the continent.
EKF said its order book is now full for 2025. It expects to deploy further investment to grow haemoglobin consumable and analyser production capacity under its five-year strategic plan.
"The additional contracts reinforce the board's confidence in delivering growth at the revenue and adjusted earnings before interest, tax, depreciation and amortisation excluding exceptional items levels for FY 2025 in-line with market expectations," said EKF Diagnostics.
The company said it understands consensus for the two measures to be GBP53.6 million and GBP12.4 million respectively. These compare with GBP50.2 million and GBP11.3 million achieved in 2024.
"As part of our five-year strategic development plan to support accelerated organic growth, we identified that haemoglobin testing was the most significant growth opportunity within our [point-of-care] portfolio. We're very pleased to see that allowing our dedicated POC sales team to focus on core growth products is bearing fruit, particularly in haemoglobin POC testing,"said Chief Executive Gavin Jones.
"As we win more and more new contracts and increase our global analyser footprint, we will see the benefits not just this year, but also in the years to come as consumable pull-through drives higher margin revenue growth," Jones continued.
By Christopher Ward, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
Ekf Diagnostics